JP2024533990A - Brmの調節に使用するためのフェノール誘導体 - Google Patents

Brmの調節に使用するためのフェノール誘導体 Download PDF

Info

Publication number
JP2024533990A
JP2024533990A JP2024507995A JP2024507995A JP2024533990A JP 2024533990 A JP2024533990 A JP 2024533990A JP 2024507995 A JP2024507995 A JP 2024507995A JP 2024507995 A JP2024507995 A JP 2024507995A JP 2024533990 A JP2024533990 A JP 2024533990A
Authority
JP
Japan
Prior art keywords
cancer
formula
compound
pharma
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533990A5 (cg-RX-API-DMAC7.html
Inventor
エリシア ビレムレ,
ヨアヒム ルドルフ,
ミンシュオ ツォン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024533990A publication Critical patent/JP2024533990A/ja
Publication of JP2024533990A5 publication Critical patent/JP2024533990A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2024507995A 2021-08-09 2022-08-08 Brmの調節に使用するためのフェノール誘導体 Pending JP2024533990A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163231220P 2021-08-09 2021-08-09
US202163231219P 2021-08-09 2021-08-09
US63/231,219 2021-08-09
US63/231,220 2021-08-09
PCT/US2022/039696 WO2023018648A1 (en) 2021-08-09 2022-08-08 Phenol derivatives for use in the modulation of brm

Publications (2)

Publication Number Publication Date
JP2024533990A true JP2024533990A (ja) 2024-09-18
JP2024533990A5 JP2024533990A5 (cg-RX-API-DMAC7.html) 2025-08-18

Family

ID=83149068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507995A Pending JP2024533990A (ja) 2021-08-09 2022-08-08 Brmの調節に使用するためのフェノール誘導体

Country Status (8)

Country Link
US (2) US11993599B2 (cg-RX-API-DMAC7.html)
EP (1) EP4384517A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024533990A (cg-RX-API-DMAC7.html)
KR (1) KR20240046498A (cg-RX-API-DMAC7.html)
AU (1) AU2022328137A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225467A1 (cg-RX-API-DMAC7.html)
TW (1) TW202321250A (cg-RX-API-DMAC7.html)
WO (1) WO2023018648A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体
JP2025525340A (ja) * 2022-06-16 2025-08-05 プレキシウム インコーポレイテッド Swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily aを分解する化合物および医薬組成物
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510851A (ja) * 2015-02-25 2018-04-19 ジェネンテック, インコーポレイテッド 治療用ピリダジン化合物およびその使用
WO2020251974A1 (en) * 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2020251971A1 (en) * 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021067606A1 (en) * 2019-10-01 2021-04-08 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2021083949A1 (en) * 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
JP2023535409A (ja) * 2020-07-21 2023-08-17 ジェネンテック, インコーポレイテッド Brm分解の抗体コンジュゲート化化学的誘導物質及びbrm分解の方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104495YA (en) 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN112996800B (zh) 2018-10-16 2024-06-25 勃林格殷格翰国际有限公司 作为smarca2和/或smarca4的降解剂的新型蛋白水解靶向嵌合体(protac)及其衍生物
FR3090393B1 (fr) 2018-12-20 2021-04-23 Ifp Energies Now Procédé de traitement d’une charge alcool pour la production d’oléfines
US20220143183A1 (en) 2019-02-23 2022-05-12 New York University Photoswitchable protacs and synthesis and uses thereof
US20230087825A1 (en) * 2019-06-10 2023-03-23 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CA3150354A1 (en) 2019-09-12 2021-03-18 Muralidhara Ramachandra METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS
EP4054724A4 (en) * 2019-10-28 2023-12-27 C4 Therapeutics, Inc. BIFUNCTIONAL CONNECTIONS
CA3167166A1 (en) 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders
JP7508578B2 (ja) 2020-04-06 2024-07-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
US12552775B2 (en) 2020-11-20 2026-02-17 Foghorn Therapeutics Inc. Compounds and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US20240150755A1 (en) 2021-02-26 2024-05-09 Salk Institute For Biological Studies Modulating regulatory t cell function in autoimmune disease and cancer
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510851A (ja) * 2015-02-25 2018-04-19 ジェネンテック, インコーポレイテッド 治療用ピリダジン化合物およびその使用
WO2020251974A1 (en) * 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2020251971A1 (en) * 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021067606A1 (en) * 2019-10-01 2021-04-08 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2021083949A1 (en) * 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
JP2023535409A (ja) * 2020-07-21 2023-08-17 ジェネンテック, インコーポレイテッド Brm分解の抗体コンジュゲート化化学的誘導物質及びbrm分解の方法

Also Published As

Publication number Publication date
US20240383897A1 (en) 2024-11-21
US20230112485A1 (en) 2023-04-13
KR20240046498A (ko) 2024-04-09
US11993599B2 (en) 2024-05-28
WO2023018648A1 (en) 2023-02-16
EP4384517A1 (en) 2024-06-19
TW202321250A (zh) 2023-06-01
US12428419B2 (en) 2025-09-30
CA3225467A1 (en) 2023-02-16
AU2022328137A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
JP7603609B2 (ja) アンドロゲン受容体を標的に分解する二官能性キメラ複素環式化合物及びその使用
ES2829636T3 (es) Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
US10450296B2 (en) Heterocyclic compounds useful as Pim kinase inhibitors
WO2023066350A1 (zh) Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
US12428419B2 (en) Therapeutic compounds
CA2889526C (en) 2-aminopyridine compounds
AU2017279027A1 (en) Chemical Compounds
EP4351558A1 (en) Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
EA019785B1 (ru) Бензофуропиримидиноны в качестве ингибиторов протеинкиназ, фармацевтические композиции, их содержащие, и их применение
WO2022003575A1 (en) Her2 mutation inhibitors
JP2019503357A (ja) IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体
JP2011507824A (ja) アンドロゲン受容体関連状態の治療に使用の二環系誘導体
JP7511097B1 (ja) Her2変異阻害薬
US12226414B2 (en) 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof
RU2683940C1 (ru) Производные имидазотиазола в качестве модуляторов активности tnf
US20250051344A1 (en) Bifunctional selective degraders of smarca2 and therapeutic uses thereof
KR20210083287A (ko) 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
JP2024089651A (ja) Her2変異阻害薬
CN117794933A (zh) 用于调节brm的酚衍生物
HK40111551A (en) Phenol derivatives for use in the modulation of brm

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260708